Sjögren's Syndrome Research Reagents

Sjögren's syndrome (SS) is a systemic autoimmune disease primarily affecting the exocrine glands, characterized by lymphocytic infiltration of salivary and lacrimal glands causing progressive sicca symptoms (dry mouth, dry eyes). Anti-SSA/Ro (Ro52/TRIM21 and Ro60/TROVE2) and anti-SSB/La autoantibodies are the serological hallmarks, with anti-Ro52 being the most prevalent specificity and carrying neonatal lupus risk in pregnant patients. Systemic manifestations include interstitial lung disease (ILD), renal tubular acidosis, peripheral neuropathy, and a 15–20 fold increased risk of B cell non-Hodgkin lymphoma. Elevated BLyS/BAFF drives pathogenic B cell survival, germinal center-like structures in salivary glands, and autoantibody production. A type I IFN signature is present in ~50% of patients. Treatment remains largely symptomatic; biologics under investigation include belimumab (anti-BLyS), ianalumab (anti-BAFFR), and rituximab (anti-CD20).

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Sjögren's Syndrome Research Reagents — key pathogenic pathways including anti-SSA/Ro and anti-SSB/La autoantibodies, salivary gland lymphocytic infiltration, BLyS/BAFF-driven B cell survival, and type I IFN signature

Fig. 1 Key pathogenic pathways in Sjögren's syndrome. Anti-SSA/Ro (Ro52, Ro60) and anti-SSB/La autoantibodies target nuclear/cytoplasmic autoantigens; BLyS/BAFF drives B cell survival and lymphoma risk; type I IFN amplifies immune activation. Key research targets highlighted in orange.

abinScience provides validated Ro52/TRIM21 and Ro60/TROVE2 recombinant proteins for anti-SSA ELISA development, SSB/La recombinant proteins, BLyS/BAFF pathway reference antibodies (belimumab, ianalumab with ELISA kit, tabalumab), and IFN-α/IFNAR antibodies for type I IFN signature research. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

Ro52/TRIM21 & Ro60/TROVE2 (Anti-SSA Autoantigens) — Anti-SSA autoantibodies targeting Ro52 (TRIM21) and Ro60 (TROVE2) are present in 60–80% of primary SS patients and are included in the ACR/EULAR classification criteria. Ro52/TRIM21 is the more prevalent specificity and is associated with neonatal lupus, congenital heart block, and ILD. abinScience offers multiple Ro52/TRIM21 recombinant proteins (3 variants with N-His tag) and Ro60/TROVE2 recombinant protein (C-His) for anti-SSA diagnostic ELISA development, epitope mapping, and Ro52/Ro60 discrimination studies.
→ Browse Ro52/TRIM21 & Ro60 proteins

SSB/La (Anti-SSB Autoantigen) — Anti-SSB/La autoantibodies target the La RNA-binding protein involved in RNA polymerase III transcription termination and are present in 30–50% of SS patients, almost always co-occurring with anti-SSA. Anti-SSB positivity is associated with longer disease duration and glandular dysfunction. Human SSB recombinant proteins (N-His and N-His-SUMO tagged) support anti-SSB diagnostic ELISA development and La protein functional research in RNA processing.
→ Browse SSB/La proteins

BLyS/BAFF / BAFFR — Elevated serum BLyS/BAFF is a hallmark of Sjögren's syndrome, driving pathogenic B cell survival, germinal center formation in salivary glands, and autoantibody production. The BLyS/BAFF pathway is the primary therapeutic target under clinical investigation. abinScience offers belimumab (anti-BLyS) and tabalumab reference antibodies, anti-belimumab polyclonal antibody, ianalumab (anti-BAFFR) reference antibody with ianalumab ELISA kit, rozibafusp alfa (anti-B7-H2/BLyS bispecific), and tibulizumab (anti-IL-17A/BLyS bispecific) for mechanism-of-action and immunogenicity research.
→ Browse BLyS/BAFF & BAFFR antibodies

IFN-α / IFNAR — A type I IFN signature is present in approximately 50% of primary SS patients and correlates with higher disease activity, anti-SSA positivity, and systemic manifestations. The IFN-α/IFNAR pathway overlaps significantly with SLE pathogenesis. Anti-IFN-α reference antibodies (sifalimumab, rontalizumab), anti-IFNAR1 reference antibodies (anifrolumab, faralimomab), and anti-IFN-α recombinant antibodies with fluorescent conjugates support IFN signature measurement, type I IFN pathway dissection, and evaluation of IFNAR blockade in SS.
→ Browse IFN-α / IFNAR antibodies

References

1. Brito-Zerón P, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016;2:16047. DOI

2. Mariette X, et al. Primary Sjögren's syndrome. N Engl J Med. 2018;378(10):931-939. DOI